Investor Relations

Financial Releases

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Reports Third Quarter 2016 Results
Revenue Increased 30% Year Over Year; Gross Margin at 85% MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the third quarter ended
View HTML
Toggle Summary Intersect ENT Schedules Third Quarter 2016 Earnings Release and Conference Call for November 2, 2016
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it plans to release third quarter financial results after market close on November 2, 2016 .
View HTML
Toggle Summary Intersect ENT Reports Second Quarter 2016 Results
Revenue Increased 27% Year Over Year; Gross Margin at 84% MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the second quarter ended
View HTML
Toggle Summary Intersect ENT Schedules Second Quarter 2016 Earnings Release and Conference Call for August 2, 2016
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it plans to release second quarter financial results after market close on August 2, 2016 .
View HTML
Toggle Summary Intersect ENT Announces Preliminary Q2 Revenue and Business Update
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced preliminary revenue for the second quarter 2016 of approximately $19.3 million , an increase of 27% from
View HTML
Toggle Summary Intersect ENT to Present at William Blair & Company 36th Annual Growth Stock Conference
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq:XENT) today announced that management will present an overview of the company's business at the 36 th Annual William Blair Growth Stock Conference . The presentation is scheduled for 12:10 p.m.
View HTML
Toggle Summary Intersect ENT Reports First Quarter 2016 Results
Revenue Increased 25% Year Over Year; Gross Margin at 81% MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the first quarter ended
View HTML
Toggle Summary Intersect ENT to Present at Bank of America Merrill Lynch 2016 Health Care Conference
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq:XENT) today announced that management will present an overview of the company's business at the 2016 Bank of America Merrill Lynch Health Care Conference . The presentation is scheduled for 3:00pm PT on May 11, 2016 , at Encore at
View HTML
Toggle Summary Intersect ENT Schedules First Quarter 2016 Earnings Release and Conference Call for May 5, 2016
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. ( NASDAQ : XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it plans to release first quarter financial results after market close on May 5, 2016 .
View HTML
Toggle Summary Intersect ENT Reports Fourth Quarter and Year 2015 Results
Full Year Revenue Increased 60% Year Over Year; Gross Margin at 80% MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the fourth
View HTML